Precision Medicine — Autologous Cell Therapies Hit Their Stride in Solid Tumors
NEW YORK – In February, cell therapy developers, researchers, and oncologists celebrated Iovance Biotherapeutics’ Amtagvi (lifileucel) US approval in advanced melanoma. As the first autologous cell therapy to win authorization in a solid tumor setting, its path to market could be a model for others to follow. “Finally, we got an adopted cell therapy for a solid tumor,” Kai He, an oncologist at Ohio State…